Please ensure Javascript is enabled for purposes of website accessibility

Can Intellia Therapeutics Turn Exciting Trial Results into Profits?

By Cory Renauer - Jun 30, 2021 at 6:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?

Shares of gene-editing pioneer Intellia Therapeutics (NTLA 1.00%) have burst higher in response to the most exciting clinical trial results the biotech industry has produced in a long time. It's still early, but it looks like the company found a way to edit troublesome genes on the fly.

Until now, experimental CRISPR-based therapies have been used to edit the genetic code contained in stem cells after they've been harvested from patients. Intellia employed the technology that underpins COVID-19 vaccines from Moderna and BioNTech to design a potential cure for a rare inherited disease, and can probably make more such cures.

Medical scientist presenting results to audience members also dressed in white.

Image source: Getty Images.

Unfortunately, drugs that interest biomedical researchers the most don't always generate blockbuster sales. Can Intellia turn landmark clinical trial data into a commercial success that pushes the stock miles higher?

It really works

On June 26, Intellia and its collaboration partner, Regeneron Pharmaceuticals (REGN 2.32%) presented interim trial results for Intellia's lead candidate, NTLA-2001. This is a potential new treatment for hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN). Patients with ATTR-PN experience severe nerve and organ damage when transthyretin, an important protein that transports vitamin A and thyroid hormones around the body, begins falling apart.

Over time, transthyretin fragments aggregate into dangerous plaques, but not for patients treated with NTLA-2001 in an ongoing dose determination trial. This revolutionary gene therapy sneaks messenger RNA (mRNA) strands to the liver; they can instruct cells to produce a CRISPR-Cas9 complex that unwinds chromosomes and disables the transthyretin gene specifically.

Just one dose of NTLA-2001 lowered transthyretin concentrations by more than half for the first three patients who received 0.1 milligrams per kilogram of body weight. Patients in the next group received a 0.3-milligram dose that lowered circulating transthyretin by a whopping 87% compared to baseline measurements.

Accidental editing of non-targeted genes is the major safety concern for Intellia and other CRISPR-focused companies that are trying to edit troublesome genes in the body. So far this hasn't been a problem for Intellia; there were no serious adverse events observed among the first six patients treated with NTLA-2001.

Scientist working under a fume hood.

Image source: Getty Images.

Now what?

The compelling trial results that sent Intellia's stock price soaring 50% on the first trading day following the big announcement were measured just 28 days after patients were treated. This is a terrific beginning, but it's going to be a long time before we know if NTLA-2001 can generate enough sales to offset Intellia's investment. This trial's primary analysis doesn't occur until two years after treatment of the last patient.

Regeneron has agreed to pay for roughly half of NTLA-2001's development expenses, but Intellia still burned through $149 million over the past year. Worldwide, there are only about 50,000 people living with hereditary amyloidosis and only a fraction of this population is diagnosed with ATTR-PN. As a gene therapy to be administered just once, Intellia needs to put a seven-figure price tag on NTLA-2001 and reach a significant portion of its addressable patient population just to break even.

Think long-term

With competition from Alnylam Pharmaceuticals' (ALNY -1.21%) Onpattro for a limited population of ATTR-PN patients, NTLA-2001 sales probably won't bring Intellia to profitability. Fortunately, Regeneron's collaboration deal with Intellia includes up to 15 targets, and the transthyretin gene is just the first.

We'll probably hear about Intellia beginning more than one study with new on-the-fly gene-editing candidates before the end of the year, which will accelerate operating expenses. It could be years before Intellia can make ends meet, but its clinical-stage pipeline is about to swell to several times its current size.

Excitement surrounding NTLA-2001 has pushed Intellia Therapeutics' market cap up to $9.1 billion at recent prices. Biotech stocks tend to trade at mid-single-digit multiples of total product sales, so success for a few new drugs is already baked into Intellia's stock price.

A high valuation right now doesn't mean that enthusiasm for a revolutionary new way to treat diseases can't drive the stock even higher. That said, investors can expect a lot of volatility between now and whenever Intellia Therapeutics actually begins earning money for its shareholders.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals and Moderna. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
$68.42 (1.00%) $0.68
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$643.29 (2.32%) $14.58
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$231.01 (-1.21%) $-2.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.